Subtype
Malignant Muscle Neoplasm
CI-CAN-00001147Explore in graph →
106 active trials1 approved drugs38 evidence items
- NCIt
- C4883
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001147Explore in graph →
Clinical trials
325 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (42)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06849986 | IO Combined With AI as First-line Treatment for Patients With Soft Tissue Sarcoma(TAIS)(TAIS) | recruiting | Phase 2 | 45 | Fudan UniversityOTHER | 1 | Jan 8, 2026 | clinicaltrials |
| NCT03526679 | Lenvatinib and Eribulin in Advanced Soft Tissue Sarcoma(LEADER) | completed | Phase 1 / Phase 2 | 30 | National Taiwan University HospitalOTHER | 1 | Dec 5, 2025 |
| clinicaltrials |
| NCT04388839 | Evolutionary Therapy for Rhabdomyosarcoma | active not recruiting | Phase 2 | 12 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Nov 26, 2025 | clinicaltrials |
| NCT06521567 | A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer | active not recruiting | Phase 1 / Phase 2 | 83 | GlaxoSmithKlineINDUSTRY | 6 | Nov 12, 2025 | clinicaltrials |
| NCT06528769 | Study of All-Trans Retinoic Acid (ATRA) and Cemiplimab in Patients With Advanced Leiomyosarcoma | recruiting | Phase 2 | 16 | Gabriel TinocoOTHER | 1 | Sep 30, 2025 | clinicaltrials |
| NCT03899805 | A Phase II Study of Eribulin and Pembrolizumab in Soft Tissue Sarcomas | completed | Phase 2 | 57 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 28, 2025 | clinicaltrials |
| NCT06683846 | Ivonescimab in the Treatment of Multiple Advanced Tumors | recruiting | Phase 2 | 400 | Fudan UniversityOTHER | 1 | Aug 24, 2025 | clinicaltrials |
| NCT05080790 | Treatment With Dinutuximab Beta, Zoledronic Acid and Low-dose Interleukin (IL-2) in Patients With Leiomyosarcoma(DiTuSarc) | completed | Phase 2 | 7 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestOTHER | 1 | Aug 17, 2025 | clinicaltrials |
| NCT06277154 | MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma | recruiting | Phase 2 | 148 | HRYZ Biotech Co.INDUSTRY | 1 | Jul 24, 2025 | clinicaltrials |
| NCT04530487 | Donor Stem Cell Transplant After Chemotherapy for the Treatment of Recurrent or Refractory High-Risk Solid Tumors in Pediatric and Adolescent-Young Adults | terminated | Phase 2 | 1 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 29, 2025 | clinicaltrials |
| NCT05269355 | A Study of Unesbulin in Participants With Advanced Leiomyosarcoma (LMS)(SUNRISELMS) | terminated | Phase 2 / Phase 3 | 359 | PTC TherapeuticsINDUSTRY | 12 | Jun 13, 2025 | clinicaltrials |
| NCT02100891 | Phase 2 STIR Trial: Haploidentical Transplant and Donor Natural Killer Cells for Solid Tumors(STIR) | terminated | Phase 2 | 15 | Monica ThakarOTHER | 1 | Mar 19, 2025 | clinicaltrials |
| NCT02428192 | Nivolumab Alone or in Combination With Ipilimumab in Treating Patients With Advanced Uterine Leiomyosarcoma | completed | Phase 2 | 20 | National Cancer Institute (NCI)NIH | 1 | Feb 25, 2025 | clinicaltrials |
| NCT04535271 | Metronomic Trabectedin, Gemcitabine, and Dacarbazine for Soft Tissue Sarcoma(TAGGED) | recruiting | Phase 2 | 80 | Sarcoma Oncology Research Center, LLCOTHER | 1 | Feb 24, 2025 | clinicaltrials |
| NCT04095221 | A Study of the Drugs Prexasertib, Irinotecan, and Temozolomide in People With Desmoplastic Small Round Cell Tumor and Rhabdomyosarcoma | completed | Phase 1 / Phase 2 | 21 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 20, 2025 | clinicaltrials |
| NCT06816771 | Evaluation of the Efficacy and Safety of Pazopanib in Combination with TGI/CIV for Recurrent or Refractory Rhabdomyosarcoma in Children or Adolescents | recruiting | Phase 2 | 38 | Shandong Cancer Hospital and InstituteOTHER | 1 | Feb 10, 2025 | clinicaltrials |
| NCT03220035 | Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial) | completed | Phase 2 | 4 | National Cancer Institute (NCI)NIH | 2 | Jan 27, 2025 | clinicaltrials |
| NCT03709680 | Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors | active not recruiting | Phase 2 | 128 | PfizerINDUSTRY | 14 | Jan 14, 2025 | clinicaltrials |
| NCT04791228 | A Pilot Study of Thermodox and MR-HIFU for Treatment of Relapsed Solid Tumors | withdrawn | Phase 2 | 0 | Children's National Research InstituteOTHER | 1 | Jan 1, 2025 | clinicaltrials |
| NCT05302921 | Neoadjuvant Dual Checkpoint Inhibition and Cryoablation in Relapsed/Refractory Pediatric Solid Tumors | completed | Phase 2 | 5 | Children's National Research InstituteOTHER | 1 | Jan 1, 2025 | clinicaltrials |
| NCT03241745 | A Study of Nivolumab in Selected Uterine Cancer Patients | completed | Phase 2 | 35 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Dec 27, 2024 | clinicaltrials |
| NCT06684327 | Multi-cohort, Single-arm Phase II Study of Albumin-paclitaxel, Ifosfamide, and Cisplatin in the Treatment of Rare Advanced Tumors | recruiting | Phase 2 | 100 | Fudan UniversityOTHER | 1 | Dec 20, 2024 | clinicaltrials |
| NCT03233204 | Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial) | completed | Phase 2 | 6 | National Cancer Institute (NCI)NIH | 2 | Dec 11, 2024 | clinicaltrials |
| NCT04996004 | A Study to Learn About the Study Medicine (Called Ontorpacept or TTI-621) Given Alone and in Combination With Doxorubicin in People With Leiomyosarcoma(TTI-621-03) | terminated | Phase 2 | 76 | PfizerINDUSTRY | 1 | Dec 11, 2024 | clinicaltrials |
| NCT02509598 | A Study of Lymphoseek® as a Lymphoid Tissue Targeting Agent in Pediatric Patients With Melanoma, Rhabdomyosarcoma, or Other Solid Tumors Who Are Undergoing Lymph Node Mapping | completed | Phase 2 | 24 | Cardinal Health 414, LLCINDUSTRY | 1 | Jun 28, 2024 | clinicaltrials |
| NCT06456892 | Effectiveness of Pucotenlimab Combined With Standard Chemotherapy Regimen | recruiting | Phase 1 / Phase 2 | 82 | Sun Yat-sen UniversityOTHER | 1 | Jun 13, 2024 | clinicaltrials |
| NCT05093322 | A Study of Surufatinib in Combination With Gemcitabine in Pediatric, Adolescent, and Young Adult Patients With Recurrent or Refractory Solid Tumors | completed | Phase 1 / Phase 2 | 13 | HutchmedINDUSTRY | 1 | Jun 7, 2024 | clinicaltrials |
| NCT03926936 | FUlvestrant in Gynecological Cancers That Are Potentially Hormone Sensitive: the FUCHSia Study(FUCHSia) | completed | Phase 2 | 17 | Frederic AmantOTHER | 2 | May 28, 2024 | clinicaltrials |
| NCT04625907 | FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma(FaR-RMS) | recruiting | Phase 1 / Phase 2 | 1,672 | University of BirminghamOTHER | 20 | May 23, 2024 | clinicaltrials |
| NCT02624388 | Study of Genistein in Pediatric Oncology Patients (UVA-Gen001)(UVA-Gen001) | terminated | Phase 2 | 4 | University of VirginiaOTHER | 1 | May 6, 2024 | clinicaltrials |
| NCT01386619 | NK DLI in Patients After Human Leukocyte Antigen (HLA)-Haploidentical Hematopoietic Stem Cell Transplantation (HSCT) | completed | Phase 1 / Phase 2 | 15 | University Hospital, Basel, SwitzerlandOTHER | 2 | Mar 19, 2024 | clinicaltrials |
| NCT01336803 | Differentiation of Bone Sarcomas and Osteomyelitis With Ferumoxytol-Enhanced MRI(Osteosarcoma) | completed | Phase 2 | 32 | Heike E Daldrup-LinkOTHER | 1 | Dec 27, 2023 | clinicaltrials |
| NCT05116683 | ATX-101 in Advanced Dedifferentiated Liposarcoma and Leiomyosarcoma(ATX-101) | terminated | Phase 2 | 4 | Benjamin IzarOTHER | 1 | Dec 6, 2023 | clinicaltrials |
| NCT03458728 | Safety, Tolerability, Efficacy and Pharmacokinetics of Copanlisib in Pediatric Patients | terminated | Phase 1 / Phase 2 | 31 | BayerINDUSTRY | 1 | Dec 4, 2023 | clinicaltrials |
| NCT02048371 | SARC024: A Blanket Protocol to Study Oral Regorafenib in Patients With Selected Sarcoma Subtypes | completed | Phase 2 | 131 | Sarcoma Alliance for Research through CollaborationOTHER | 1 | Nov 7, 2023 | clinicaltrials |
| NCT02584309 | Doxorubicin With Upfront Dexrazoxane for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma | completed | Phase 2 | 73 | Washington University School of MedicineOTHER | 1 | Nov 7, 2023 | clinicaltrials |
| NCT05094804 | A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents | unknown | Phase 1 / Phase 2 | 172 | OncoResponse, Inc.INDUSTRY | 1 | Nov 2, 2023 | clinicaltrials |
| NCT02304458 | Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas | completed | Phase 1 / Phase 2 | 140 | National Cancer Institute (NCI)NIH | 2 | Oct 17, 2023 | clinicaltrials |
| NCT03420014 | Treatment of Metastatic Soft Tissue Sarcoma (STS) Patients (FIBROSARC USA)(FIBROSARC US) | unknown | Phase 2 | 114 | Philogen S.p.A.INDUSTRY | 1 | Oct 10, 2023 | clinicaltrials |
| NCT02095132 | Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors | completed | Phase 1 / Phase 2 | 76 | National Cancer Institute (NCI)NIH | 2 | Sep 26, 2023 | clinicaltrials |
| NCT05174455 | Niraparib for the Treatment of Leiomyosarcoma | withdrawn | Phase 2 | 0 | David Liebner, MDOTHER | 0 | Sep 18, 2023 | clinicaltrials |
| NCT03718091 | M6620 (VX-970) in Selected Solid Tumors | completed | Phase 2 | 30 | Massachusetts General HospitalOTHER | 1 | Jul 7, 2023 | clinicaltrials |
| NCT02275286 | Trabectedin Plus Radiotherapy in Soft Tissue Sarcoma Patients(TRASTS) | recruiting | Phase 1 / Phase 2 | 199 | Grupo Espanol de Investigacion en SarcomasOTHER | 3 | May 31, 2023 | clinicaltrials |
| NCT04730349 | A Study of Bempegaldesleukin (BEMPEG: NKTR-214) in Combination With Nivolumab in Children, Adolescents and Young Adults With Recurrent or Treatment-resistant Cancer(PIVOT IO 020) | terminated | Phase 1 / Phase 2 | 15 | Bristol-Myers SquibbINDUSTRY | 6 | Mar 24, 2023 | clinicaltrials |
| NCT05708391 | Radiotherapy Combined With Realgar-Indigo Naturalis Formula (RIF) in the Treatment of Rhabdomyosarcoma(RMS) in Children | unknown | Phase 2 | 53 | Xinhua Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 0 | Feb 1, 2023 | clinicaltrials |
| NCT02601209 | Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma | terminated | Phase 1 / Phase 2 | 151 | National Cancer Institute (NCI)NIH | 1 | Aug 23, 2022 | clinicaltrials |
| NCT03245450 | Study Evaluating the Safety and Efficacy of Eribulin Mesilate in Combination With Irinotecan Hydrochloride in Children With Refractory or Recurrent Solid Tumors | completed | Phase 1 / Phase 2 | 40 | Eisai Inc.INDUSTRY | 8 | Jun 28, 2022 | clinicaltrials |
| NCT03074318 | Avelumab and Trabectedin in Treating Patients With Liposarcoma or Leiomyosarcoma That is Metastatic or Cannot Be Removed by Surgery | terminated | Phase 1 / Phase 2 | 35 | Fred Hutchinson Cancer CenterOTHER | 1 | Apr 29, 2022 | clinicaltrials |
| NCT03041701 | Insulin-like Growth Factor 1 Receptor (IGF-1R) Antibody AMG479 (Ganitumab) in Combination With the Src Family Kinase (SFK) Inhibitor Dasatinib in People With Embryonal and Alveolar Rhabdomyosarcoma | terminated | Phase 1 / Phase 2 | 14 | National Cancer Institute (NCI)NIH | 1 | Apr 14, 2022 | clinicaltrials |
| NCT02050919 | Sorafenib Tosylate, Combination Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With High-Risk Stage IIB-IV Soft Tissue Sarcoma | completed | Phase 2 | 20 | OHSU Knight Cancer InstituteOTHER | 1 | Mar 21, 2022 | clinicaltrials |
Data updated 22 days agoSource updated Jan 8, 2026source: clinicaltrials